why choose us

First received: June 19, 2025

Clinical Trial: Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors.

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Refractory Malignant Solid Tumors
mRNA Vaccine
Interleukin

Study Type: INTERVENTIONAL


Official Title: A Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Antitumor Activity of IL - 22BP in Refractory Malignant Solid Tumors.

Brief Summary: This study aims to investigate the safety and efficacy of the IL-22BP in patients with refractory malignant solid tumors.

Read more